Positive results from a study of ivacaftor (Kalydeco®) in children ages 1 to 2 were announced today.
Site Search
Two Phase 3 clinical trials of tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) showed positive results, Vertex Pharmaceuticals announced today.
Learning that your baby has cystic fibrosis may come as a shock, especially if you do not have a family history of the disease, but you are not alone.
Managing cystic fibrosis can feel overwhelming at times — but we’re here to help. Learn how to navigate life with CF.
Vascular access devices, or PICCs and ports, allow repeated and long-term access to the bloodstream for frequent or regular administration of drugs, like intravenous (IV) antibiotics.
Today, Vertex Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted its application to expand Trikafta® (elexacaftor/tezacaftor/ivacaftor) to include children ages 6-11 years old with cystic fibrosis who have at least one F508del or a mutation in the CFTR gene that is responsive based on in vitro data. The FDA has granted priority review of the application and has indicated that it will make a decision by June 8, 2021.
Starting solid foods is very important for the development and health of babies with cystic fibrosis.
At this age, you will want to start serving high-calorie finger foods and gradually boost calories with safe solid foods. It is important to create a routine and set time limits at mealtime.